Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Breakthrough Electroneutron Multi-Response Miniature Dosimetry/Spectrometry in Medical Accelerator Publisher Pubmed



Sohrabi M1 ; Malekitakbolagh M1 ; Nedaei HA2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Health Physics and Dosimetry Research Laboratory, Department of Energy Engineering and Physics, Amirkabir University of Technology, Tehran, Iran
  2. 2. Department of Radiotherapy Oncology, Cancer Institute, University of Medical Sciences, Tehran, Iran

Source: Scientific Reports Published:2024


Abstract

Breakthrough multi-response miniature dosimetry/spectrometry of electroneutrons (EN) was made on surface and in-depths of whole-body polyethylene phantom under 10 cm × 10 cm electron beam of 20 MV Varian Clinac 2100C electron medical accelerator commonly applied for prostate treatment. While dosimetry/spectrometry of photoneutrons (PN) has been well characterized for decades, those of ENs lagged behind due to very low EN reaction cross section and lack of sensitive neutron dosimeters/spectrometers meeting neutron dosimetry requirements. Recently, Sohrabi “miniature neutron dosimeter/spectrometer” and “Stripe polycarbonate dosimeter” have broken this barrier and determined seven EN ambient dose equivalent (ENDE) (µSv.Gy–1) responses from electron beam and from albedo ENs including beam thermal (21 ± 2.63), albedo thermal (43 ± 3.70), total thermal (64 ± 6.33), total epithermal (32 ± 3.90), total fast (112.00), total thermal + epithermal (l96 ± 10), and total thermal + epithermal + fast (208 ± 10.23) ENs. Having seven ENDE responses of this study and seven PNDE responses of previous study with the same accelerator obtained at identical conditions by the same principle author provided the opportunity to compare the two sets of responses. The PNDE (µSv.Gy–1) responses have comparatively higher values and 22.60 times at isocenter which provide for the first time breakthrough ENDE responses not yet reported in any studies before worldwide. © The Author(s) 2024.